Tongshu Gene, Ruijian Medicine, and DeepModeling Secure Over RMB 100 Million in Recent Funding Rounds

Oct 14, 2024 19:03 CST Updated 19:03

iRegene Therapeutics

Cell Therapy Product Developer

DP Technology

Simulation R&D Platform Developer

TONGSHU GENE Completes Over 100 Million RMB in Series D Financing,Advance Cancer Treatment into the New Era of Precision Medicine

Recently, Wuxi Tongshu Biotechnology Co., Ltd. (hereinafter referred to as TONGSHU GENE) has officially completed a D-round financing of over 100 million RMB. This round of financing was led by Wuxi Liangxi Science and Innovation Industry Investment Fund (managed by Bohua Capital), with follow-up investment from Jiangsu Jiandao Venture Capital Co., Ltd. The funds will mainly be used for the company to continuously strengthen R&D investment, expand production scale, develop market channels, and enhance brand influence.

TONGSHU GENE has been deeply engaged in the field of genetic testing for 7 years, adhering to a hospital-centric "product + service" strategy. Starting from clinical needs, it has developed a series of IVD diagnostic technologies with extremely high technical barriers. In the field of IVD in vitro diagnostics product development, TONGSHU GENE possesses a comprehensive and complete technology platform with extensive and in-depth technical coverage.

Based on the core concept technology of multi-platform innovation, IVD products with core technical advantages have been developed in the fields of first-generation sequencing platforms, second-generation sequencing platforms, fluorescent quantitative PCR, and CRISPR.

TONGSHU GENE's self-developed microsatellite instability (MSI) detection kit obtained the first Class III medical device registration certificate for MSI testing in China in January 2021, gaining a first-mover advantage in the field of tumor testing across 17 types of cancers including gastric cancer, colorectal cancer, and breast cancer.

In March 2024, TONGSHU GENE successfully launched its full-site osimertinib companion diagnostic kit, filling a gap in China. The kit uses the non-ARMS-PCR method and MASS patented technology to accurately identify EGFR gene mutations, providing reliable evidence for precise lung cancer treatment.

iRegene Completes Over 100 Million Yuan in B-Round Financing to Advance Cell Therapy New Drug Development

On October 14, iRegene (Wuhan Ruijian Pharmaceutical Technology Co., Ltd.) announced the completion of a Series B financing round exceeding 100 million yuan. This round was jointly led by Ceyuan Capital and Guosheng Capital, with participation from well-known industry investment institutions and Wuhan Optics Valley Industrial Investment. Meanwhile, iRegene's Series B+ financing is nearing its final stage and is expected to close soon.

iRegene Focuses on the Development of Universal Chemically Induced Cell Therapy Drugs. According to the press release, the funds from this round of financing will be used to accelerate the advancement of the company's Parkinson's disease treatment products NouvNeu001/NouvNeu003 and ophthalmic treatment product NouvSight001 in clinical trials in both China and the United States, while strengthening the R&D progress of multiple innovative pipelines and the establishment of clinical capabilities.

iRegene, founded in 2017, is an international innovative biopharmaceutical company focusing on the field of regenerative medicine. The company leverages a unique technology platform to concentrate on small molecule chemical transcriptional regulation.Induced Pluripotent Stem Cells (iPSC), with a pipeline covering multiple potential "first-in-class" products in neurodegenerative diseases, ophthalmology, and more.

NouvNeu001 Injection, independently developed by iRegene, is a chemically induced functional type of human dopaminergic neuron precursor cells. It is also the world's first universal cell therapy product based on chemical induction to enter the clinical stage in the field of Parkinson's disease. In August 2023, the product received approval from the National Medical Products Administration (NMPA) of China to conduct a combined Phase 1/2 clinical study. So far, the subjects have shown good safety and generally demonstrated significant improvements in motor function and quality of life. In June this year, the product received approval in the United States.FDAApproval for Clinical Use。

In the field of neurodegenerative diseases, iRegene has also developed another research product, NouvNeu003. In December 2023,NouvNeu003 has been approved by NMPA for clinical trials, targeting indications primarily for early-onset Parkinson's patients with an onset age of less than 50.。

Beyond neurodegenerative diseases, iRegene continues to explore in other disease areas. In March this year, the company's breakthrough ophthalmology product NouvSight001 received orphan drug designation from the FDA. This product is the first universal iPSC-derived cell therapy developed by iRegene for ophthalmology, intended for the treatment of "retinitis pigmentosa-related indications."

State-owned Assets Boost DP Technology in Completing a New Round of Financing Worth Hundreds of Millions

DP Technology recently announced the completion of a new round of financing worth hundreds of millions of RMB, with investors including the Beijing Artificial Intelligence Industry Investment Fund and Zhongguancun Science City Company. This round of financing not only injected capital into the company but, more importantly, it signifies that DP Technology's dedication and phased achievements in the AI for Science field have gained strong recognition and support from state-owned capital.

DP Technology is a leader and practitioner in the AI for Science research paradigm, dedicated to using AI to learn scientific principles and knowledge to solve key problems in scientific research and industrial R&D. The company, relying on its deep cultivation in interdisciplinary fields, has built the "Deep Potential·Universe®" AI for Science large model system, promoting research methods to transition from the "experimental trial and error / computer" era into the "pre-trained model era."

The funds from this round of financing will be mainly used to attract top talent, deepen the full-stack capabilities from original algorithm innovation to industrial software and industry solutions, and strengthen the industrial application and commercial promotion of technology in scenarios such as biomedicine, new energy, chemical industry, and semiconductors. Wei Jie Sun, founder and CEO of DP Technology, stated that AI for Science is the fifth paradigm of scientific research, which has already driven scientific research, continuously expanded the boundaries of cognition, and will apply more advanced results to actual production.

With the support of state-owned assets, DP Technology will gain broader development space and richer resources, continue to uphold the concept of "technology empowering industry," promote research and application in the AI for Science field, and contribute to building China into a strong technological power.

Editor: Cheng Lin